RxDoctor Payments Data

Larry Leslie, MD

Interventional Cardiology · Naples, FLNPI 1669419990

Payments from drug & device makers

$45,332in general payments, 2019–2025

Across 308 payments — averaging $147.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$28K
  • Johnson & Johnson$12K
  • Edwards Lifesciences$1K
  • Novartis$673
  • Alnylam Pharmaceuticals Inc.$534
  • Abiomed$447
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$34,63576%
  • Travel & lodging$3,6278%
  • Food & beverage$7,07016%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,332 in reported general payments places this provider in the 75th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$432,903
Medicare patients
996
Services billed
3,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab692$613,122
EliquisApixaban242$337,352
EntrestoSacubitril/Valsartan209$309,217
XareltoRivaroxaban220$264,463
JardianceEmpagliflozin205$178,262
OzempicSemaglutide144$141,363
Praluent PenAlirocumab101$76,756
MounjaroTirzepatide67$68,851
WegovySemaglutide34$65,135
NexletolBempedoic Acid62$31,979
VascepaIcosapent Ethyl26$16,802
Rosuvastatin Calcium1,144$16,724
Nebivolol Hcl243$14,908
Repatha SyringeEvolocumab15$14,525
CrestorRosuvastatin Calcium13$9,632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$337,352242 claims
NovartisEntresto$673$309,217209 claims
Johnson & JohnsonXarelto$11,826$264,463220 claims
Novo NordiskOzempic, Wegovy$85$206,498178 claims
Boehringer IngelheimJardiance$291$178,262205 claims
Lilly USA, LLCMounjaro$18$68,85167 claims
Esperion Therapeutics, Inc.Nexletol$90$31,97962 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →